CFTR and cystic fibrosis: Most pharmacological approaches targeting CF were directed at correcting the defect in ion transport by stimulating chloride secretion.[5] Thanks to better symptomatic treatments with anti‐inflammatory and antibiotic drugs, as well as to the introducion of new CFTR modulator drugs in the 2010s, life expectancy has improved, especially in high income countries.[6] Yet, as lately noted by Addissouky and coworkers, symptomatic treatments remain essential, because pre‐existing organ damage cannot be reversed by CFTR modulators.[7]